We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.
Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. ...
We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.
Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Our novel oral formulation is unlocking new market opportunities and the potential to significantly improve the quality of life of patients who currently have few treatment options.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.